Table 3.
Official name | Normal breast tissue (n = 8) | ER+ breast tumors (n = 85) | ER−breast tumors (n = 68) | ER+/ER− | |
---|---|---|---|---|---|
FC | p-value | ||||
11 up-regulated miRNAs selected in the screening series | |||||
miR-190b | 1.0 (0.32-1.57) | 6.34 (0.71-32.3) | 0.27 (0.02-6.23) | 23.30 | <0.0001 |
miR-101-1 | 1.0 (0.69-8.05) | 0.30 (0.05-2.10) | 0.15 (0.01-0.92) | 2.01 | <0.0001 |
miR-193b | 1.0 (0.43-1.79) | 1.44 (0.10-9.17) | 1.00 (0.11-4.45) | 1.43 | 0.0191 |
miR-342-5p | 1.0 (0.78-2.16) | 2.03 (0.29-19.4) | 0.93 (0.10-3.65) | 2.18 | <0.0001 |
miR-376c | 1.0 (0.52-3.04) | 0.14 (0.02-1.55) | 0.10 (0.02-0.83) | 1.43 | 0.0064 |
miR-451 | 1.0 (0.32-11.1) | 0.17 (0.02-14.0) | 0.14 (0.01-9.77) | 1.23 | ns |
miR-143 | 1.0 (0.45-2.72) | 0.21 (0.03-1.40) | 0.14 (0.02-0.74) | 1.52 | 0.0140 |
miR-30c2 | 1.0 (0.69-1.72) | 0.54 (0.12-3.06) | 0.34 (0.09-1.17) | 1.60 | <0.0001 |
miR-30e | 1.0 (0.70-2.98) | 0.79 (0.12-4.57) | 0.47 (0.10-2.28) | 1.68 | <0.0001 |
miR-26a1 | 1.0 (0.77-4.06) | 0.34 (0.11-1.78) | 0.09 (0.02-0.47) | 3.64 | <0.0001 |
miR-26b | 1.0 (0.68-4.38) | 0.49 (0.15-2.93) | 0.34 (0.06-1.64) | 1.44 | 0.0008 |
7 down-regulated miRNAs selected in the screening series | |||||
miR-654-3p | 1.0 (0.72-1.34) | 0.30 (0.05-2.68) | 0.66 (0.04-17.8) | −2.16 | <0.0001 |
miR-203 | 1.0 (0.51-2.43) | 0.88 (0.02-5.78) | 1.51 (0.05-19.6) | −1.72 | 0.0059 |
miR-146a | 1.0 (0.54-3.71) | 0.70 (0.07-3.63) | 0.95 (0.10-4.30) | −1.36 | 0.0344 |
miR-494 | 1.0 (0.85-2.17) | 0.65 (0.02-6.96) | 0.69 (0.02-9.03) | −1.07 | ns |
miR-338-5p | 1.0 (0.79-1.78) | 0.84 (0.19-4.66) | 0.96 (0.12-5.08) | −1.15 | ns |
miR-891a | 1.0 (0.77-1.64) | 1.37 (0.14-8.43) | 2.07 (0.37-15.5) | −1.51 | ns |
miR-1244 | 1.0 (0.73-1.69) | 1.23 (0.16-5.11) | 2.34 (0.35-25.3) | −1.91 | <0.0001 |
12 miRNAs selected from the literature | |||||
let-7a | 1.0 (0.73-1.79) | 0.58 (0.15-2.00) | 0.47 (0.11-2.99) | 1.24 | 0.0055 |
let-7b | 1.0 (0.71-1.69) | 0.53 (0.08-2.04) | 0.31 (0.04-0.82) | 1.75 | <0.0001 |
miR-18a | 1.0 (0.49-3.33) | 0.50 (0.06-2.53) | 1.12 (0.12-23.9) | −2.24 | <0.0001 |
miR-18b | 1.0 (0.47-4.45) | 0.50 (0.07-3.52) | 1.04 (0.13-25.3) | −2.07 | <0.0001 |
miR-19a | 1.0 (0.70-2.13) | 0.34 (0.03-2.61) | 0.42 (0.02-14.4) | −1.24 | ns |
miR-21 | 1.0 (0.49-5.26) | 2.05 (0.41-16.6) | 1.84 (0.21-9.53) | 1.12 | ns |
miR-22 | 1.0 (0.38-4.51) | 0.71 (0.12-12.9) | 0.66 (0.09-3.36) | 1.08 | ns |
miR-92a1 | 1.0 (0.68-1.40) | 0.32 (0.10-1.17) | 0.49 (0.09-8.95) | −1.54 | <0.0001 |
miR-155 | 1.0 (0.55-4.24) | 2.06 (0.52-10.9) | 3.97 (0.35-32.0) | −1.93 | <0.0001 |
miR-206 | 1.0 (0.01-2.28) | 0.25 (0.02-7.71) | 0.32 (0.01-2.74) | −1.29 | ns |
miR-221 | 1.0 (0.65-1.92) | 0.40 (0.07-4.24) | 0.53 (0.05-5.55) | −1.31 | ns |
miR-222 | 1.0 (0.63-2.30) | 0.39 (0.06-2.68) | 0.50 (0.04-3.88) | −1.28 | ns |
Results in ER+ and ER− tumors are expressed as the median (range) of miRNA level relative to normal breast tissues. For each miRNA, we report the fold-change (FC) between ER+ and ER− tumors and the p-value associated to Mann–Whitney test (ns for not significant)